Advances in understanding and management of Erdheim-Chester disease

Aniruddha Murahar Kulkarni,Prasanna Kumar Reddy Gayam,Jesil Mathew Aranjani
DOI: https://doi.org/10.1016/j.lfs.2024.122692
IF: 6.78
2024-05-08
Life Sciences
Abstract:Erdheim Chester Disease (ECD) is a rare histiocytic disorder marked by infiltration of organs with CD68 + histiocytes. ECD stems from mutations of BRAF and MAP2K1 in hematopoietic stem and progenitor cells (HSPCs), which further differentiate into monocytes and histiocytes. Histopathology reveals lipid-containing histiocytes, which test positive for CD68 and CD133 in immunohistochemistry. Signs and symptoms vary and depend on the organ/s of manifestation. Definitive radiological results associated with ECD include hairy kidney, coated aorta, and cardiac pseudotumor. Treatment options primarily include anti-cytokine therapy and inhibitors of BRAF and MEK signaling.
pharmacology & pharmacy,medicine, research & experimental
What problem does this paper attempt to address?